ABVC BioPharma Receives $100,000 Milestone Payment in Vitargus Licensing Deal

ABVC BioPharma has received a $100,000 licensing payment from ForSeeCon Eye Corporation under their global licensing agreement for Vitargus®, bringing total cash payments received to $495,000. The comprehensive deal structure includes $30 million in equity consideration through 5 million ForSeeCon shares, $3.5 million in total cash licensing payments, and potential royalties up to $60 million based on 5% of net sales if the product reaches commercialization.

The financial implications of this agreement are significant for ABVC, providing both immediate liquidity through cash payments and long-term revenue potential through equity holdings and future royalties. With $3 million in additional cash payments still available and substantial royalty opportunities, the company has secured a licensing arrangement with total potential proceeds of $63.5 million. This blended financial structure supports ABVC's strategic positioning in the ophthalmology market while offering transformational shareholder value potential.

Vitargus® represents a disruptive innovation in ophthalmic surgery as the world's first biodegradable vitreous substitute designed for retinal detachment procedures. Unlike current silicone oil or gas bubble solutions that require patients to maintain face-down positioning during recovery, Vitargus® is naturally absorbed and allows patients to maintain upright vision. This technological advancement addresses significant patient comfort concerns while potentially improving surgical outcomes.

The commercial opportunity for Vitargus® is substantial within the growing vitreous substitute and retinal surgery markets. According to Verified Market Reports, the global vitreous substitute market was valued at approximately $2.5 billion in 2024 and is projected to reach $4.1 billion by 2033, expanding at a 6.3% compound annual growth rate. The broader retinal surgery devices market, where Vitargus® would compete, was estimated at $2.82 billion in 2024 and expected to grow to $4.76 billion by 2030 at a 9.2% CAGR according to Grand View Research.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the milestone payment highlights continued progress in the Vitargus® licensing collaboration, noting the company's strategic positioning to capture both near-term financial benefits and long-term commercial upside. Jerry Chang, CEO of ForSeeCon Eye Corporation, added that the payment reflects confidence in the product's regulatory and commercial trajectory as it continues to generate global interest.

The agreement strengthens ABVC's foundation in ophthalmology while addressing the multi-billion dollar global market for retinal disease treatments detailed in market research. By combining immediate cash flows with long-term revenue streams through equity, milestone payments, and royalties, ABVC has structured a comprehensive financial arrangement that supports both current operations and future growth initiatives in the competitive ophthalmic surgery market.